Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Stock Has Average Price Target of $46.50 According to Analysts

Key Points

• Analysts are broadly bullish on DMRA: Twelve analysts give the stock a consensus “Buy” rating, with an average 12-month price target of $46.50.
• The stock was trading at $18.43, down 0.7%, well below its analyst target and its 12-month high of $38.33. The company reported a quarterly loss of $0.39 per share, beating estimates of a $0.45 loss.
• Insider and institutional activity was positive: CEO Jennifer Jarrett bought 12,500 shares, while institutional investors—including Braidwell LP and Seven Fleet Capital—opened new positions.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) has been assigned a consensus rating of "Buy" from the twelve analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $46.50.

A number of equities research analysts have weighed in on the stock. Jefferies Financial Group initiated coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They set a "buy" rating and a $50.00 price target for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. HC Wainwright reaffirmed a "buy" rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Wedbush reaffirmed an "outperform" rating and set a $40.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, September 29th. Finally, TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a "strong-buy" rating in a report on Monday, August 24th.

Damora Therapeutics, Inc. Common Stock Trading Down 0.7%

Shares of DMRA opened at $18.43 on Thursday. The firm has a market cap of $1.14 billion, a P/E ratio of -5.47 and a beta of 1.43. Damora Therapeutics, Inc. Common Stock has a 12-month low of $4.95 and a 12-month high of $38.33. The company's 50-day moving average price is $25.90 and its 200 day moving average price is $25.82.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.39) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.06. Equities research analysts forecast that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current year.

Insider Transactions at Damora Therapeutics, Inc. Common Stock

In other news, CEO Jennifer Jarrett purchased 12,500 shares of the firm's stock in a transaction on Friday, September 25th. The shares were bought at an average cost of $20.23 per share, for a total transaction of $252,875.00. Following the completion of the purchase, the chief executive officer directly owned 512,500 shares of the company's stock, valued at approximately $10,367,875. This trade represents a 2.50% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

A number of institutional investors have recently modified their holdings of the company. Braidwell LP purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at $42,146,000. Seven Fleet Capital Management LP acquired a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth about $7,398,000. Squarepoint Ops LLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at about $303,000. Finally, Arizona State Retirement System purchased a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at about $260,000. 14.20% of the stock is owned by institutional investors and hedge funds.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.